Skip to main content
PharmAbcine Inc. logo

PharmAbcine Inc. — Investor Relations & Filings

Ticker · 208340 ISIN · KR7208340000 KO Manufacturing
Open in API
Filings indexed 461 across all filing types
Latest filing 2021-07-02 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 208340

About PharmAbcine Inc.

http://pharmabcine.com/

PharmAbcine Inc. is a clinical-stage biotechnology company specializing in the development of fully human therapeutic monoclonal antibodies (mAbs). The company focuses on creating innovative treatments for diseases with high unmet medical needs, primarily in oncology, neovascular eye diseases, and other inflammatory and vascular disorders. Utilizing its proprietary human antibody library and discovery technologies, PharmAbcine advances a pipeline of next-generation IgG-based therapeutics. The company's mission is to contribute to human health by providing novel antibody-based drugs to patients.

Recent filings

Filing Released Lang Actions
[기재정정]주요사항보고서(유무상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) from PharmAbcine, specifically detailing a correction (정정신고) to a previously filed capital increase (유무상증자결정). It outlines changes to payment dates, listing dates, and shareholder record dates for both paid-in and bonus share issues. Since this is a formal regulatory filing regarding capital structure changes and share issuance, it falls under the 'Share Issue/Capital Change' category.
2021-07-02 Korean
[기재정정]증권신고서(지분증권) (2021.08)
Capital/Financing Update Classification · 98% confidence The document is a '증권신고서(지분증권)' (Securities Registration Statement for Equity Securities) filed by PharmAbcine. It contains detailed information regarding a capital increase (rights offering), including issuance conditions, schedules, and risk factors. This is a formal regulatory filing required by the Financial Supervisory Service (FSS) in South Korea for public offerings. Since it is a comprehensive regulatory document detailing the terms of a securities issuance rather than a simple announcement of a report, it falls under the 'Regulatory Filings' category.
2021-07-02 Korean
기타경영사항(특허권취득)(자율공시)(항-VISTA 항체 및 이의 용도)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent ('항-VISTA 항체 및 이의 용도') by PharmAbcine. It details the patent's content, the patent holder, the acquisition date, and future utilization plans. Since this is a specific corporate announcement regarding a business development (patent acquisition) that does not fit into financial reporting, M&A, or governance categories, it falls under the general regulatory filing category.
2021-06-22 Korean
[기재정정]증권신고서(지분증권) (2021.08)
Capital/Financing Update Classification · 95% confidence The document is a 'Correction Report' (정정신고) for a 'Securities Registration Statement' (증권신고서) filed by PharmAbcine (주)파멥신. It explicitly mentions 'Correction of Securities Registration Statement' (증권신고서(지분증권) 기재정정) and provides a table of contents for the corrections made to the original filing. In the context of Korean financial regulations (DART system), a 'Securities Registration Statement' is a regulatory filing related to capital raising (equity issuance). Since it is a formal regulatory filing document rather than a mere announcement of a report, it falls under the category of Regulatory Filings (RNS).
2021-06-18 Korean
주주명부폐쇄기간또는기준일설정
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding the setting of a record date for shareholder registry closure due to a capital increase (rights offering). This type of corporate action announcement, which does not fit into specific categories like dividend announcements or director dealings, is classified as a general regulatory filing.
2021-06-07 Korean
주권매매거래정지(무상증자)
Share Issue/Capital Change Classification · 100% confidence The document is a short regulatory notice regarding the suspension of stock trading for PharmAbcine due to a bonus issue (무상증자). It cites specific KOSDAQ market regulations and provides the duration of the suspension. Since it is a regulatory announcement regarding trading status and does not fit into specific categories like M&A or share issuance (it is a suspension notice), it falls under the general regulatory filing category.
2021-06-04 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.